Genmab — Juni 2014
-
altså monoterapistudiet tror jeg ikke fejler. Det er singlearm studiet der bare måler responser mv.
-
Head to Head studierne som vi får data på i 2016-2018 timeframe op mod Revlimid og Velcade er der ALTID risiko i. Randomiserede studier med en hård kontrolarm er aldrig nemme
-
men succes der lukker op for de store guldmønter
-
Ja det kan bruges til at booste specielt CDC mekanismen for antistoffer, men både ofatumumab og daratumumab er optimeret til at have en god CDC, så hvor meget man vinder ved et hexaboost i klinikken er nok svært at sige, men i princippet ja. Dertil hører en klinisk pakke som vi ikke kender størrelsen på
-
-
WIPO - Search International and National Patent Collections
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections. This search facility features: flexible search syntax; automatic word stemming and relevance ranking; as well as graphical results.
(patentscope.wipo.int)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind